Severe Vincristine-related Neurotoxicity in 5 Patients with Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome

Dana Egan-Sherry, Roma Bhuta, Peter D. Cole, Lisa M. Gennarini, Justine M. Kahn, Maria Luisa Sulis, Bradley D. Denardo, Jennifer J.G. Welch

Research output: Contribution to journalArticlepeer-review

Abstract

Vincristine, a key agent in the treatment of many pediatric malignancies, causes sensory, motor and autonomic neuropathy. We report the clinical courses of 5 patients who required cessation of vincristine after developing severe neurotoxicity during treatment for acute lymphoblastic leukemia. All 5 patients lost the ability to ambulate and 3 had additional severe neurotoxic side effects including vision loss and vocal cord dysfunction. Although prior literature reports poor outcomes for children in whom vincristine was discontinued during acute lymphoblastic leukemia therapy, all 5 patients described here achieved and have maintained complete continuous remission.

Original languageEnglish (US)
Pages (from-to)E997-E999
JournalJournal of Pediatric Hematology/Oncology
Volume43
Issue number7
DOIs
StatePublished - Oct 1 2021

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Keywords

  • acute lymphoblastic leukemia
  • neurotoxicity
  • vincristine

Fingerprint

Dive into the research topics of 'Severe Vincristine-related Neurotoxicity in 5 Patients with Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome'. Together they form a unique fingerprint.

Cite this